# Cannabidiol-rich extract suppresses the activation of proinflammatory genes IL-1β and IL-6 in equine mesenchymal stem cells stimulated with lipopolysaccharide

**Authors:** Beatriz da Costa Kamura, Lucas Vinícius de Oliveira Ferreira, Natielly Dias Chimenes, João Pedro Marmol de Oliveira, Diego Noe Rodriguez-Sanchez, Márcio de Carvalho, Rogério Martins Amorim

PMC · DOI: 10.1007/s11259-026-11105-7 · Veterinary Research Communications · 2026-02-24

## TL;DR

CBD extract reduces inflammation in horse stem cells exposed to a bacterial compound, potentially aiding nerve injury recovery.

## Contribution

CBD-rich extract selectively modulates proinflammatory and neurotrophic gene expression in equine mesenchymal stem cells.

## Key findings

- CBD extract reduced IL-1β and IL-6 gene expression in equine MSCs after LPS stimulation.
- BDNF gene expression increased at 48 hours with CBD priming, while NGF decreased.
- CBD priming preserved cell metabolism and selectively affected specific genes.

## Abstract

Peripheral nerve injuries (PNI) often lead to long-term functional impairment. Mesenchymal stem cells (MSCs) and cannabidiol (CBD) have shown anti-inflammatory and neuroprotective effects in vitro, which may be relevant for PNI research. The aim of this study was to evaluate CBD-rich cannabis extract’s potential to induce anti-inflammatory and neurotrophic gene expression in equine adipose tissue-derived MSCs (EqAT-MSCs) in an inflammatory in vitro environment. The morphology and metabolic activity of EqAT-MSCs (n = 4) were assessed after CBD-rich extract priming at concentrations of 3, 5, 7, and 9 µM for 24 and 48 h. Cytokine and neurotrophic gene expression was evaluated under these conditions: DMEM (unprimed), DMEM + LPS (lipopolysaccharide) (10 ng/ml), and LPS (10 ng/ml) + DMEM + CBD at 3, 5, and 7 µM for 24 and 48 h. No morphological changes were observed in primed EqAT-MSCs versus unprimed cells. EqAT-MSCs showed a reduction in metabolic activity at 9 µM after 24 h. CBD priming following LPS stimulation led to statistically significant changes in EqAT-MSC gene expression. BDNF expression increased after 48 h (3 and 5 µM), while NGF expression decreased at both 24 and 48 h (3, 5, and 7 µM). IL-1β expression decreased after 24 h (3 and 7 µM), and IL-6 levels decreased at both 24 (5 and 7 µM) and 48 h (3, 5, and 7 µM). No significant changes were observed in GDNF, TNF-ɑ, IFN-ɣ, or IL-10. These results indicate that CBD-rich extract selectively modulates inflammatory and neurotrophic gene expression in EqAT-MSCs while maintaining metabolic integrity.

## Linked entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553], IL6 (interleukin 6) [NCBI Gene 3569], BDNF (brain derived neurotrophic factor) [NCBI Gene 627], NGF (nerve growth factor) [NCBI Gene 4803], GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668], IL10 (interleukin 10) [NCBI Gene 3586]
- **Chemicals:** cannabidiol (PubChem CID 644019)
- **Species:** Equus caballus (taxon 9796)

## Full-text entities

- **Genes:** TNF-alpha [NCBI Gene 100033834], ACTB [NCBI Gene 100033878], GAPDH [NCBI Gene 100033897], CD44 [NCBI Gene 100034221], CD105 [NCBI Gene 100070421], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, GDNF [NCBI Gene 100067053], IL-6 [NCBI Gene 100034196], NGF [NCBI Gene 100065669], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL-10 [NCBI Gene 100034187], CD34 [NCBI Gene 100051718], BDNF [NCBI Gene 100009689], IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL-1beta [NCBI Gene 100034237], IFN-gamma [NCBI Gene 100034181], interleukin 1 beta [NCBI Gene 100052414], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}
- **Diseases:** lesions of the peripheral nervous system (MESH:D010523), cytotoxicity (MESH:D064420), hypoxia (MESH:D000860), inflammation (MESH:D007249), PNI (MESH:D059348)
- **Chemicals:** CO2 (MESH:D002245), LPS (MESH:D008070), DMSO (MESH:D004121), CBD (MESH:D002185), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MESH:C022616), CBD-rich cannabis extract (-), penicillin (MESH:D010406), MTT (MESH:C070243), water (MESH:D014867), TRIzol (MESH:C411644), F12 (MESH:C007782), Delta9-tetrahydrocannabinol (MESH:D013759), streptomycin (MESH:D013307)
- **Species:** Equus caballus (domestic horse, species) [taxon 9796], Homo sapiens (human, species) [taxon 9606], Cannabis sativa (species) [taxon 3483], Escherichia coli (E. coli, species) [taxon 562], Canis lupus familiaris (dog, subspecies) [taxon 9615]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932370/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932370/full.md

---
Source: https://tomesphere.com/paper/PMC12932370